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Abstract
Background: To implement total body irradiation (TBI) using volumetric modulated arc therapy (VMAT). We applied
the Varian RapidArc™ software to calculate and optimize the dose distribution. Emphasis was placed on applying a
homogenous dose to the PTV and on reducing the dose to the lungs.
Methods: From July 2013 to July 2014 seven patients with leukaemia were planned and treated with a VMAT-based
TBI-technique with photon energy of 6 MV. The overall planning target volume (PTV), comprising the whole body, had
to be split into 8 segments with a subsequent multi-isocentric planning. In a first step a dose optimization of each
single segment was performed. In a second step all these elements were calculated in one overall dose-plan,
considering particular constraints and weighting factors, to achieve the final total body dose distribution. The
quality assurance comprised the verification of the irradiation plans via ArcCheck™ (Sun Nuclear), followed by in
vivo dosimetry via dosimeters (MOSFETs) on the patient.
Results: The time requirements for treatment planning were high: contouring took 5–6 h, optimization and dose
calculation 25–30 h and quality assurance 6–8 h. The couch-time per fraction was 2 h on day one, decreasing to
around 1.5 h for the following fractions, including patient information, time for arc positioning, patient positioning
verification, mounting of the MOSFETs and irradiation. The mean lung dose was decreased to at least 80 % of the
planned total body dose and in the central parts to 50 %. In two cases we additionally pursued a dose reduction of 30
to 50 % in a pre-irradiated brain and in renal insufficiency. All high dose areas were outside the lungs and other OARs.
The planned dose was in line with the measured dose via MOSFETs: in the axilla the mean difference between
calculated and measured dose was 3.6 % (range 1.1–6.8 %), and for the wrist/hip-inguinal region it was 4.3 %
(range 1.1–8.1 %).
Conclusion: TBI with VMAT provides the benefit of satisfactory dose distribution within the PTV, while selectively
reducing the dose to the lungs and, if necessary, in other organs. Planning time, however, is extensive.
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Introduction
Total body and total marrow irradiation (TBI, TMI) are
well-established parts of several conditioning regimens
required prior to bone marrow (BMT) or allogeneic
stem cell transplantation (HSCT). In addition to killing
malignant cells TBI/TMI suppresses the immune system
and thus helps to prevent transplant rejection.
In comparison to one-dose applications hyper-
fractionated treatments result in lower side effects
[1, 2]. Various dose- and fractionation-schemes were
used in the past [3–5]. In general total doses from 12 to
15 Gy in 6 to 11 fractions were reported (e.g. [6–9]).
Different methods are in use, such as irradiation from
the right and left side, while the patient is sitting in a
specially adapted chair [10, 11]; other institutes carry out
irradiation in the supine and prone position with the pa-
tient lying on a fixed couch on the floor or on a moving
couch with the translation of the patient through the
open beam [12]. Several publications report on TBI and
TMI calculations with emphasis on dose distribution
[13, 14]. An excellent review on the design and develop-
ment of dosimetric issues from 1980 to 2014 was pub-
lished recently [15]. The authors included a few papers
on organ complications and immune deficiency after
TBI or TMI and/or stem cell transplantation.
The translational method was improved by Quast et
al. [16, 17]. Unfortunately our treatment rooms are too
small to fit the moving couch equipment. Jahnke et al.
[18] use an arc approach with a fixed field size. In the
above mentioned TBI techniques homogeneity may pos-
sibly be jeopardized by varying body diameters. In par-
ticular when using lateral fields the dose distribution in
the lungs may be quite irregular and might differ vastly
from the dose that is planned to be absorbed in that
organ.
Lately two high precision techniques were introduced:
Helical tomotherapy was implemented for TBI and TMI
some years ago [19–22] as an approach to reduce the
dose to critical organs, especially the lung. Furthermore
feasibility studies were carried out for planning TMI
with VMAT combined with ventro-dorsally opposed
fixed beams for the legs [23], an idea which may be
transferred to TBI as well.
Already in 2010 the bone-marrow- and stem-cell-
transplantation-centre (SCTC) of the Elisabethinen Hos-
pital in Linz, Austria, approached the management of
our hospital to have TBI performed at our radiation
oncology department. The years before patients with
leukaemia had to be sent to the University Clinics in
Vienna or Innsbruck, Austria, for TBI. Ambulance
transport and hospitalization for some days in a foreign
environment has many disadvantages for these immuno-
suppressed patients: the travel included the risk of infec-
tions and implied a physical and mental burden for these
critically ill patients. To change this uncomfortable situ-
ation for the benefit of the patients was the major factor
to implement TBI at our institution.
After various site visits of TBI Centers in Austria and
abroad two factors were decisive to use VMAT (RapidArc™):
on the one hand our treatment rooms are too small to use
a translational couch and on the other hand the dosimetric
aspects concerning the lung seemed to us unsatisfactory
both for this couch method and for the bi-lateral treatment
with a patient sitting on a chair. This is why we imple-
mented a VMAT-only-approach for standard TBI patients.
During a period of several months we performed calcula-
tions on dummy CT image sets via VMAT/RapidArc™ and
in July 2012 we started TBI in our first leukaemia
patient using a slightly different treatment concept. In July
2013 we started to perform TBIs according to a prospective
treatment plan in line with the referring hospital. An
average of 5 to 7 patients per year was announced by the
Elisabethinen Hospital, Linz. Until February 1st 2016 twenty
patients were treated with this method.
Our approach for TBI is to use pure VMAT via mul-
tiple overlapping arcs, a method which may be of benefit
for several radiation oncology centres with similar archi-
tectural circumstances. The benefit for the patients may
be on the one hand no transport to centres 200 km and
further away, and on the other hand a high precision
3D-treatment with the advantage – in comparison to
conventional methods - of applying a homogenous total
body dose and to spare the lung and, if necessary, also
other organs.
Herein we report on set-up and dosimetry details as
well as on early clinical data of our first seven patients
treated with this VMAT-TBI.
Materials and methods
Between July 2013 and June 2014, seven patients, three
with acute lymphatic leukaemia (ALL), two with acute
myeloid leukaemia (AML) and two presenting with
T-cell lymphoma, underwent allogeneic stem cell trans-
plantation following TBI based myeloablative conditioning
at the Elisabethinen Hospital, Linz, Austria. Patients with
ALL were treated according to the “GMALL protocol”
[24]. Patients with AML received induction chemotherapy
with Ara-C and an anthracyclin. The mean patient-age at
TBI was 30.6 years (20–52 years). Three patients were
referred in first CR (complete remission), 2 in second CR,
one with partial remission and one patient suffered from
relapsed T-cell lymphoma.
Contouring
The planning target volume (PTV) was contoured using
the outer body contour, excluding the lung (except a
small margin of lung tissue adjacent to the ribs and
spine to ensure full dose coverage of the ribs). Both
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lungs were contoured using the pulmonary windows.
The right and left lung were contoured separately, but
they were considered as one structure for lung dosim-
etry analysis. Small vessels extending beyond the hilar
regions were included. To steer the optimizer for lung
sparing small helping structures inside the lung were
used. However, for dose statistics and DVH, the anatom-
ical lungs are the relevant structures. Other organs at
risk (OAR) were not routinely contoured and involved
in dose optimization, except for two cases: one patient
had received whole brain irradiation with 24 Gy
3.3 months before TBI; therefore brain sparing was
intended. In another patient the mean dose to both kid-
neys was restricted due to pre-existing renal insufficiency.
Additional helping structures within the overlapping re-
gions were contoured and used for steering the optimizer
leading to an improved dose distribution in those areas.
Positioning and immobilization
For each patient two computed tomography (CT) image
sets (SOMATOM Sensation 16™, Siemens, Erlangen,
Germany) were performed, with a slice thickness of
10 mm in the first 3 patients and of 5 mm in the follow-
ing patients. Since the CT scan length of the available
CT is only 160 mm, it was necessary to split the image
sets into a cranial and a caudal body section to accom-
plish treatment of the whole body length. The patient
was positioned on a vacuum mattress (VacFix™, PAR Sci-
entific A/S, Odense, Denmark) placed into a custom
made wooden box, in order to guarantee a stable
mattress from the start of the planning procedure until
the last treatment fraction. For the head-, neck- and
shoulder-regions thermoplastic masks are used. Add-
itional thermoplastic bolus material was placed on the
head mask, the sternum, the shinbones and knees to en-
sure a sufficient dose to superficial bones (assigned in
Fig. 1). Further, the patient was covered with elastic gel
bolus mattings to achieve an adequate skin dose.
Treatment planning and irradiation
The primarily planned dose to the overall PTV was
13.2 Gy, administered in eight fractions, which are
1.65 Gy per fraction and 3.3 Gy per day. This dose and
fractionation regimen was well established at the Fred
Hutchinson Cancer Research Center and Seattle Cancer
Care Alliance (Seattle. WA, USA) and is a standard con-
ditioning therapy in almost all allogeneic transplantation
centres worldwide, including the Medical University
Vienna (personal communications). The dose of 13.2 Gy
TBI is used for transplants from an unrelated donor, in
case of related donors the planned total dose is reduced
to 12 Gy.
The interval between two fractions per day was a
minimum of 6 h. Irradiation was performed at photon
energy of 6 MV. For the lungs a mean dose of 10 Gy or
lower had to be achieved. Therefore we used additional
helping structures inside the lungs with low constraint
values to steer the optimizer for lung sparing.
The TBI treatment plans were generated using the
RapidArc™ software, provided within the Eclipse™ treat-
ment planning system, version 10.0 (Varian Medical
Systems, Palo Alto, CA) on a cluster of six T5400
workstation personal computers with 8-way 2.5 GHz
Intel Pentium III processor and 24 GB of RAM. The
Fig. 1 Different CT slices of the cranial part of patient H.L. The arrows indicate the positions of the thermoplastic and gel boluses. The colour
wash presentation of the dose distribution shows the dose reductions of up to 50 % in the lung and the kidneys. In patient H.L. the kidneys were
spared due to pre-TBI renal insufficiency
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progressive resolution optimization algorithm, version
10.0.28 (PRO, Varian Medical Systems, Palo Alto,
CA), was used to optimize all RapidArc™ plans. This
software version allows the simultaneous optimization
of a maximum of 10 arcs in one calculation process.
The final dose calculation was performed with the an-
isotropic analytical algorithm (AAA), version 10.0.28.,
using a grid size of 0.25 cm.
The splitting of the planning CT images into a cranial
and a caudal part necessitated a dosimetric alignment of
these two body parts. The overall PTV had to be split
into 8 segments (Seg1 to 8) with a subsequent multi-
isocentric planning. The number of iso-centres was 9 to
15, dependent on the body mass index of the patient.
Figure 2 shows a patient with 12 iso-centres.
Because of the above mentioned limitation of optimiz-
ing a maximum of 10 arcs or a total sum of 3600° within
one single plan and the splitting into two CT-image
groups, the treatment planning required the calculation
of two field alignments, one in the lower mediastinum
and the other in the lower pelvis (Fig. 3). For the prox-
imal four segments from head to upper pelvis the patient
was treated in the head first supine position. Then the
patient was rotated 180° to irradiate the patient in the
feet first supine position from feet to alignment zone II
in the pelvis, according to segments 5 to 8. In a first step
the optimization of each single segment was carried out
separately. All arcs had an overlap of at least 2 cm into
the neighbouring segment to avoid hot and cold spots
at the junction areas. Segments with one iso-centre
(Seg1,6,7,8) were planned with two full arcs (179–
181°), whereas segments planned with two coplanar
iso-centres (e.g. Seg2–5 in Fig. 2) were calculated with
two half arcs, at each iso-centre. In general, the combin-
ation of collimator rotations of 0° and 90° were used for
all arcs. The maximum field size was limited to 30 ×
40 cm. In a second step all these segments (Seg1–8) had
to be calculated in one overall plan.
Due to irregular dose distributions in these overlap-
ping zones an extra calculation process was necessary
to homogenize the dose using the “Convert Isodose
Level to Structure”-mode of the Eclipse™ treatment
planning system. These structures were used in the
subsequent VMAT optimization for increasing or de-
creasing the dose in areas with insufficient or excessive
dose, respectively. The evaluation of the final treatment
plan was carried out by creating a plan sum of the cra-
nial and the caudal CT images. Remaining over- or
under dosages in the junction area between the cranial
and caudal part were removed by drawing helping
structures, which were used for de- or increasing the
dose in these areas, respectively, in another optimization
step. The final plan was accepted when no dose “islands”
with doses smaller than 95 % of the prescribed dose were
present inside the PTV, with the lowest dose maximum
achievable.
Fig. 2 Field (yellow rectangulars) and iso-centre (red dots) arrangement: for the treatment planning the CT image set is divided into 8 segments
(Seg1–8, indicated by the red lines and the numbers), with one iso-centre in segments 1, 6, 7 and 8, and with two coplanar iso-centres in
segments 2 to 5. In segment 2, the field dimensions for 90° collimator rotation are indicated
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The quality assurance comprises the verification of the
dose distribution of each iso-centre via ArcCheck™ (Sun
Nuclear Corporation, Melbourne, FL, USA), requiring the
calculation and export of the verification plans and the
measurements themselves. During treatment in vivo
dosimetry is performed via an appropriate positioning
of metal-oxide-semiconductor field-effect transistors
(MOSFETs) on the patient. Two MOSFETs are placed in
the axilla and two additional ones between wrists and hips
or inguinal region to avoid any air gap between the
MOSFETs and the skin. Subsequently the measured dose
values are compared with the planned doses.
Before irradiation the position of the patient was veri-
fied on the basis of bony alignment for each iso-centre
separately using the Varian On-Board Imager™ (OBI)
kilovoltage imaging system. In most cases the position of
the patient was accurate (±2.5 mm), with the exception
of the arm’s position, which had to be corrected 3 times.
Haematological cell transplantation
Three to 5 days after TBI allogeneic stem cell transplant-
ation was performed. The patients were hospitalized at
the sterile ward of the stem cell transplantation unit for
5 to 6 weeks. Patients were discharged following
hematologic engraftment and in the absence of severe
acute GvHD (graft vs. host disease).
Results
The time requirement for treatment planning was high:
contouring took 5–6 h, dose calculation and optimizing
amounted to 25–30 h and quality assurance took 6–8 h.
With regard to contouring, the manual separation of the
outer contour of the patient’s body (the PTV), from the
other parts like the couch, the bolus or the head mask on
each of the up to 250 slices of the CT image for the cranial
as well as caudal part was most time consuming. Quality
assurance comprised several tasks, namely the calculation
and export of the verification plans for the ArcCheck™
measurements at each iso-centre, the measurements
themselves, and the MOSFET measurements during ir-
radiation plus subsequent comparison with the planned
doses. The couch-time per fraction was 2 h on day one,
including step-by-step information to the patient regard-
ing the current process, time of arc positioning, patient
positioning verification with OBI, the mounting of the
MOSFETs and irradiation of all segments, decreasing to
around 1.5 h for the following fractions. The net irradi-
ation time per full arc was 1 min. Two arcs were per-
formed in each iso-centre. In the thoracic segments half
arcs with a treatment time of 0.5 min each were used.
Four patients received a total dose of 13.2 Gy (8 frac-
tions twice daily). One received only 9.9 Gy (6 fractions
in 3 days) due to chemotherapy toxicities. Two patients
were treated to 8 Gy in 4 fractions, due to their general
condition. In the patient presenting with renal insuffi-
ciency the mean dose to both kidneys could be reduced
to 7 to 8 Gy (Figs. 1 and 4). In the patient with a previ-
ous brain irradiation the dose to the central brain area
was reduced to 6 Gy, whereas the mean dose was re-
stricted to 11.7 Gy.
Fig. 3 Dose distribution of the whole body (patient H.L.) in colour wash: overview of the 2 field alignment areas. Due to irregular dose distributions in
these overlapping zones an extra calculation process was necessary to achieve homogenous doses and to avoid over- and under-dosages
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Table 1 presents the mean dose to the PTV and the
D95% of the PTV, in addition the mean doses and the
D90% of both lungs, whereby D95% and D90% represent
the dose coverage of the 95 % volume of the PTV and of
the 90 % volume of the lung in Gy, respectively. In none
of the patients the mean lung dose was above 10.7 Gy.
The mean volumes in the whole body exceeding 110,
120 and 130 % of the prescribed PTV dose were 62.7 %
(range 42–81.7 %), 10.8 % (range 3.5–19.7 %) and 1.6 %
(range 0.13–4 %) of the PTV, respectively. All areas that
received more than 120 % of the prescribed dose were
outside the lungs. Small areas outside the OARs with a
maximum dose of 130 % were accepted, whereas a mean
of 1.6 % of the PTV received more than 130 % of the
prescribed dose for all patients. The 1.6 % volume com-
prises all these small areas (see Table 2).
The planned dose was in line with the measured dose
via MOSFETs: in the axilla the mean difference between
calculated and measured dose was 3.6 % (range 1.1–
6.8 %), and for the wrist/hip-inguinal region it was 4.3 %
(range 1.1–8.1 %). In Table 2 the percentages of the PTV
receiving 90, 95, 110, 120 and 130 % of the dose are
listed; e.g. 98.6 % (range 97.0–99.9 %) of the PTV re-
ceived 95 % of the planned dose.
Side effects and effectiveness
The mean follow-up after TBI of all patients is
8.0 months (2.3–15.0 months). During radiotherapy all
patients suffered from slight to moderate fatigue, and all
presented with a pre-existing light anaemia. No other
side effects during treatment were observed. Immedi-
ately after TBI all patients suffered from G3 mucositis
and received high dose analgesic therapy; one patient
presented with bladder inflammation for a week. No
modest or severe lung reaction was observed during
follow-up. One patient, who was treated during relapse
without obtaining a remission after chemotherapy, died
of refractory disease 2.3 months after TBI. One add-
itional patient with ALL relapsed 8.8 months after treat-
ment (mediastinum, neck nodes) and died after
13.4 months. The other 5 patients live disease free and
without severe toxicities.
Improvements in treatment planning
The following improvements in the planning proce-
dures were carried out while gathering experience with
VMAT-TBI: As VMAT is a high-precision irradiation
technique, the slice thickness of the CT images was re-
duced from 10 to 5 mm to increase resolution of the dose
distribution, for example in the lungs, where structure
sizes (margins) as small as 10 mm were used in the dose
optimization process.
The field arrangement in the thoracic region (lung) ac-
quired special attention due to the intended lung spar-
ing. Dividing the large 30 × 40 cm fields into two
separate fields with a size of 15 × 40 cm was found to be
Fig. 4 Dose volume histograms of the primary target volume (red)
and lung (blue) for all patients. The solid lines represent the mean
values; the error bars the standard deviation. Green lines: kidneys of
patient H.L. (dose reduction)
Table 1 Mean doses (in the cranial half of the patients) of PTV
and OARs in Gy and dose coverage of the 95 % volume of the
PTV (D95%) and of the 90 % volume of the lung (D90%) in Gy
Pat. PTV PTV Lung right Lung left
Dmean D95% Dmean D90% Dmean D90%
Gy Gy Gy Gy Gy Gy
D.D. 14.7 13.1 10.7 8.3 10.6 7.8
D.F. 13.9 12 10.5 5.6 10.4 5.7
E.F.a 11.4 10.3 9.6 7.3 9.9 7.5
H.L. 14.1 11.1 10.6 5.9 10.6 5.6
H.S. 14.5 12.8 10.5 5.8 10.7 6
E.D.b 9.1 8.3 6.8 5.0 6.9 4.8
L.W.b 9.2 8.4 7.3 4.5 7.2 4.7
aIn patient E.F. the planned target dose was 9.9 Gy due to
chemotherapy toxicities
bPatient E.D./L.W. was treated with 8 Gy only due to his general condition and
performance status
Table 2 Percentage of the PTV receiving 90 %, 95 %, 110 %,
120 % and 130 % of the prescribed dose, respectively
Pat. 90 % 95 % 110 % 120 % 130 %
D.D. 99.7 98.5 64.0 10.7 0.13
D.F. 98.6 97.0 42.0 3.5 0.4
E.F. 99.9 99.9 78 15.4 2.1
H.L. 99.5 98.2 49.3 5.2 3.7
H.S. 98.9 98.6 48.9 6.1 0.5
E.D. 99.0 98.5 81.7 19.7 4.0
L.W. 99.9 99.6 75.1 14.9 0.2
Mean 99.4 98.6 62.7 10.8 1.6
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optimum for lung sparing. The smaller dimension of the
field size (15 cm) was located in the direction of the mo-
tion of the MLCs. This is indicated in Fig. 2 for a colli-
mator rotation of 90°, where the field was separated into
a cranial and a caudal part with 15 × 40 cm field size
each and an overlap of 2 cm. The overlap region of 2 cm
was used to guarantee a homogeneous dose in the abut-
ting region. With this geometry, the MLCs could shield
the lungs in an ideal way; additionally the smaller field
sizes allowed for a better dose modulation taking advan-
tage of the full MLC motion (e.g., over travel restriction
with larger fields). When central parts of the lung re-
ceived 50 % of the described dose, dose sparing was
found to be optimum, however, this is only possible
when using small fields.
To obtain an adequate skin dose a total-body gel bolus
with a thickness of 5 mm was used from the third pa-
tient on, analogue to the use of a bolus in standard ir-
radiation techniques.
Discussion
VMAT generates adequate dose distributions even for
complexly shaped PTVs. The challenge to use VMAT for
TBI is the extremely large extension of the PTV requir-
ing multiple overlapping arc treatments. After the initial
introduction and learning phase we are at present treat-
ing about one patient per month with this technique.
Admittedly, the time requirements for VMAT-TBI are
high. Even with up-to-date work stations pure calcula-
tion time for plan optimization and dose calculation is
very long. We hope that in the near future, the time for
calculation and optimization in VMAT-TBI can be de-
creased due to the availability of faster computers. With
regard to treatment time, 1.5 h per fraction (2 h for the
first fraction) in VMAT-TBI are not far away from the
treatment time using a translational couch, which is in
the range of 1 to 2 h, depending on additional electron
fields used to boost the ribs [25].
On the other hand VMAT-TBI results in state-of-the-
art 3D-CT-based treatment planning with the option of
selectively lowering or increasing the dose to particular
regions of the body. Except for the lungs this might be
relevant in pre-irradiated regions, in pre-existing severe
organ insufficiency or –with respect to increasing the
dose- in regions with a high burden of tumour. VMAT-
TBI may help to reduce pneumonitis-related morbidity
and mortality, but this has to be evaluated in a larger set
of patients. VMAT or tomotherapy seem to be currently
the best high precision techniques for 3D-TBI. VMAT/
RapidArc™ and even helical tomotherapy are not able to
cover the whole body without repositioning the patient,
thus exact dose planning and dose delivery in these
overlapping regions remains a challenging issue.
A further advantage of VMAT-TBI is that no add-
itional devices to translate the patient through the beam
are necessary. Patient positioning and beam delivery are
carried out with the same system thus eliminating po-
tential sources of error. VMAT-TBI can be delivered in
any treatment room that is large enough to fit a linear
accelerator.
The VMAT method described in this paper was intro-
duced in our department in July 2012 treating a TMI
case on an individual basis. TBI concept was developed
in close cooperation with the local transplantation team.
From June 2013 until July 2014 we applied it for TBI in
7 leukaemia patients. All of them presented with a low
rate of acute side effects. For long term efficacy and late
effects further follow-up is necessary.
Whether a dose reduction in the brain, the kidneys or
in other organs is a remarkable improvement with re-
gard to (late) side effects and whether these dose reduc-
tions do not lead to an increase of (extra-medullary)
recurrence rates, are open questions. However, Kim et
al. [26] could recently demonstrate in 101 patients re-
ceiving tomotherapy for TMI that doses lower than
10 Gy in organs at risk did not increase the rate of
extra-medullary recurrences. Thus selectively reducing
the dose in critical organs might be an option to reduce
side effects without compromising cure rates. Patients
with malignant myeloma might benefit most from
VMAT, because the target volume - in comparison to
TBI - may be limited to the bone marrow and the in-
ternal organs might be spared from the high dose region
as much as possible [19–24, 26–29].
Conclusion
TBI with VMAT up to 13.2 Gy in fractions of 1.65 Gy is
feasible and associated with a so far low rate of early
toxicity. The reason to use VMAT was twofold: The
treatment rooms are too small to install a translational
couch. Moreover RapidArc™ guarantees a homogenous
dose to the total body and allows 3D conformal high
precision RT and a selective reduction of the dose to the
lungs to mean doses of 10 Gy or below. However, add-
itional resources for treatment planning with regard to
personnel and time are high. The implementation of
TBI in the region is a great advantage and an additional
benefit for the community. It prevents these critically ill
patients from long distance to other centres and there-
fore prevents them from the risk of infections as well as
from additional physical and mental distress.
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